Potential surrogate endpoint for B-cell hematologic malignancy: A systematic review and meta-analysis
Abstract Confirming the patient benefit of progression-free survival (PFS) in B-cell non-Hodgkin lymphoma (B-NHL) and multiple myeloma (MM) has become increasingly challenging due to the improved outcomes brought by novel therapies. In parallel, the U.S. Food and Drug Administration recommends condu...
Saved in:
| Main Authors: | Satoshi Hirano, Keisuke Hanada, Hideki Maeda |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-06-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-05053-6 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
COEXISTENCE OF RENAL CELL CARCINOMA AND HEMATOLOGICAL MALIGNANCIES
by: Gokhan Sargin, et al.
Published: (2014-08-01) -
Therapeutic Benefits of Lenalidomide in Hematological Malignancies
by: Mohammed Shafi Abdulsalam, et al.
Published: (2019-04-01) -
ROLE OF POLYMORPHISMS OF TOLL-LIKE RECEPTORS SIGNALING PATHWAY GENES IN THE DEVELOPMENT OF HEMATOLOGICAL MALIGNANCIES
by: E. L. Nazarova, et al.
Published: (2017-09-01) -
Editorial: Rare hematological malignancies
by: Pier Paolo Piccaluga, et al.
Published: (2025-04-01) -
Global, regional, and national economic burden of hematologic malignancies (1990–2021) with projections to 2050
by: Zhexian Li, et al.
Published: (2025-06-01)